{"id":"clofibride","rwe":[],"tags":[{"label":"clofibride","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"C10AB10","category":"atc"},{"label":"Active","category":"status"},{"label":"Anticholesteremic Agents","category":"pharmacology"},{"label":"Antimetabolites","category":"pharmacology"},{"label":"Hypolipidemic Agents","category":"pharmacology"},{"label":"Lipid Regulating Agents","category":"pharmacology"}],"phase":"phase_2","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"lipenan","offLabel":[],"synonyms":["clofibride","lipenan"],"timeline":[],"approvals":[],"brandName":"Lipenan","ecosystem":[],"mechanism":{"modality":"Small Molecule","drugClass":"clofibride","explanation":"Think of it like a brake on a car - Lipenan slows down the liver's production of triglycerides, which are a type of fat that can build up in the blood and increase the risk of heart disease. By reducing triglyceride levels, Lipenan can help lower the risk of heart problems. This is especially important for people with high levels of triglycerides in their blood.","oneSentence":"Lipenan works by inhibiting the synthesis of triglycerides in the liver.","technicalDetail":"Lipenan is a fibric acid derivative that acts as a peroxisome proliferator-activated receptor alpha (PPARα) agonist, which leads to the inhibition of acyl-CoA:diacylglycerol acyltransferase (DGAT) and other enzymes involved in triglyceride synthesis."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/696","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=CLOFIBRIDE","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=CLOFIBRIDE","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T10:11:57.615059","biosimilars":[],"competitors":[{"drugName":"clofibrate","drugSlug":"clofibrate","fdaApproval":"1967-02-08","genericCount":5,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"gemfibrozil","drugSlug":"gemfibrozil","fdaApproval":"1981-12-21","genericCount":18,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"fenofibrate","drugSlug":"fenofibrate","fdaApproval":"1993-12-31","patentExpiry":"May 31, 2033","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"choline fenofibrate","drugSlug":"choline-fenofibrate","fdaApproval":"2008-12-15","genericCount":12,"patentStatus":"Off-patent — generic available","relationship":"same-class"}],"genericName":"clofibride","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"clofibrate","brandName":"clofibrate","genericName":"clofibrate","approvalYear":"1967","relationship":"same-class"},{"drugId":"gemfibrozil","brandName":"gemfibrozil","genericName":"gemfibrozil","approvalYear":"1981","relationship":"same-class"},{"drugId":"fenofibrate","brandName":"fenofibrate","genericName":"fenofibrate","approvalYear":"1993","relationship":"same-class"},{"drugId":"choline-fenofibrate","brandName":"choline fenofibrate","genericName":"choline fenofibrate","approvalYear":"2008","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT06905626","phase":"PHASE3","title":"Weight Gain Prevention in Adolescents and Young Adults","status":"NOT_YET_RECRUITING","sponsor":"University of Minnesota","startDate":"2026-06-01","conditions":["Healthy Volunteers"],"enrollment":140,"completionDate":"2031-03-31"},{"nctId":"NCT04298203","phase":"PHASE2","title":"Role of Pharmacotherapy in Counteracting Weight Regain in Adolescents With Severe Obesity","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Minnesota","startDate":"2021-08-04","conditions":["Obesity"],"enrollment":100,"completionDate":"2027-06-30"},{"nctId":"NCT05834062","phase":"PHASE2","title":"Phentermine/Topiramate as Preventive Pharmacotherapy for Obesity","status":"WITHDRAWN","sponsor":"University of Minnesota","startDate":"2023-10-17","conditions":["Obesity, Adolescent"],"enrollment":0,"completionDate":"2027-08"},{"nctId":"NCT02714062","phase":"PHASE4","title":"A Pharmacokinetic Study Comparing VI-0521 With Placebo in Obese Adolescents","status":"COMPLETED","sponsor":"VIVUS LLC","startDate":"2016-03","conditions":["Pediatric Obesity","Childhood Obesity"],"enrollment":42,"completionDate":"2016-11"},{"nctId":"NCT02553824","phase":"PHASE1","title":"FDA Approved Medication to Reduce Binge Eating and/or Purging","status":"COMPLETED","sponsor":"Stanford University","startDate":"2015-10-30","conditions":["Binge Eating Disorder","Bulimia Nervosa"],"enrollment":22,"completionDate":"2017-04-15"},{"nctId":"NCT02229214","phase":"PHASE4","title":"Effect of VI-0521 (Qsymia®) on Glomerular Filtration Rate (GFR) in Overweight or Obese Healthy Subjects","status":"COMPLETED","sponsor":"VIVUS LLC","startDate":"2014-08","conditions":["Obesity"],"enrollment":51,"completionDate":"2014-11"},{"nctId":"NCT01703741","phase":"PHASE3","title":"A Multicenter Extension Trial to Evaluate the Safety of Testosterone Gel","status":"COMPLETED","sponsor":"Ferring Pharmaceuticals","startDate":"2012-12","conditions":["Adult Male Hypogonadism"],"enrollment":145,"completionDate":"2013-10"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"NDDF":"005944","UNII":"0S9SLS3L93","CHEBI":"CHEBI:135401","INN_ID":"3245","UMLSCUI":"C0055909","ChEMBL_ID":"CHEMBL1697831","KEGG_DRUG":"D07188","DRUGBANK_ID":"DB13849","PUBCHEM_CID":"160134","MESH_DESCRIPTOR_UI":"D002995","MESH_SUPPLEMENTAL_RECORD_UI":"C007089"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":12,"therapeuticAreas":["Gastroenterology"],"atcClassification":{"source":"DrugCentral","atcCode":"C10AB10","allCodes":["C10AB10"]},"biosimilarFilings":[],"recentPublications":[],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Lipenan, also known as CLOFIBRIDE, is a small molecule drug in the clofibride class. It is a lipid-lowering agent, but its exact target and approved indications are unknown. The commercial status of Lipenan is unclear, and it may be patented or generic. Key safety considerations are not well-documented. Further research is needed to fully understand its pharmacology and clinical use.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}